High titers of both rheumatoid factor and anti-CCP antibodies at baseline in patients with rheumatoid arthritis are associated with increased circulating baseline TNF level, low drug levels, and reduced clinical responses: a post hoc analysis of the RISING study

Autor: Takashi Inui, Tohru Abe, Nobuyuki Miyasaka, Takao Koike, Toru Yoshinari, Toshiro Yano, Tsutomu Takeuchi
Jazyk: angličtina
Rok vydání: 2017
Předmět:
0301 basic medicine
musculoskeletal diseases
Adult
Male
medicine.medical_specialty
lcsh:Diseases of the musculoskeletal system
Gastroenterology
Anti-Citrullinated Protein Antibodies
Arthritis
Rheumatoid
03 medical and health sciences
0302 clinical medicine
Pharmacokinetics
Double-Blind Method
immune system diseases
Internal medicine
Post-hoc analysis
medicine
Rheumatoid factor
Humans
Rheumatoid arthritis
skin and connective tissue diseases
Autoantibodies
Retrospective Studies
030203 arthritis & rheumatology
business.industry
Tumor Necrosis Factor-alpha
Middle Aged
medicine.disease
Infliximab
Rheumatology
Titer
030104 developmental biology
Antirheumatic Agents
Immunology
Clinical response
Tumor necrosis factor alpha
Female
lcsh:RC925-935
business
Prediction
Anticyclic citrullinated peptide antibodies
Biomarkers
medicine.drug
Research Article
Zdroj: Arthritis Research & Therapy
Arthritis Research & Therapy, Vol 19, Iss 1, Pp 1-11 (2017)
ISSN: 1478-6362
1478-6354
Popis: Background Although both rheumatoid factor (RF) and anticyclic citrullinated peptide antibodies (anti-CCP) are useful for diagnosing rheumatoid arthritis (RA), the impact of these autoantibodies on the efficacy of tumor necrosis factor (TNF) inhibitors has been controversial. The aim of this post hoc analysis of a randomized double-blind study (the RISING study) was to investigate the influences of RF and anti-CCP on the clinical response to infliximab in patients with RA. Methods Methotrexate-refractory patients with RA received 3 mg/kg of infliximab from weeks 0 to 6 and then 3, 6, or 10 mg/kg every 8 weeks from weeks 14 to 46. In this post hoc analysis, patients were stratified into three classes on the basis of baseline RF/anti-CCP titers: “low/low-C” (RF
Databáze: OpenAIRE
Externí odkaz: